CYP2C9*3/*3 Gene Expression Affects the Total and Free Concentrations of Valproic Acid in Pediatric Patients with Epilepsy

References

• Valproic acid [package insert]. Maple Grove, MN: Upsher-Smith Laboratories, Inc; 2016.
   Google Scholar
• Goldenberg MM. Overview of drugs used for epilepsy and seizures: etiology, diagnosis, and treatment. P&T. 2010;35:392–415.
   PubMedGoogle Scholar
• Hilal-Dandan R, Brunton LL. Pharmacotherapy of the epilepsies. In: Goodman and Gilman’s Manual of Pharmacology and Therapeutics. 2nd ed. New York: McGraw-Hill Education; 2016.
   Google Scholar
• Beydoun A, Sackellares J, Shu V. Safety and efficacy of divalproex sodium monotherapy in partial epilepsy a double-blind, concentration-response design clinical trial. Neurology. 1997;48(1):182–188. doi:10.1212/WNL.48.1.182
   Web of Science ®Google Scholar
• Nasreddine W, Beydoun A. Valproate-induced thrombocytopenia: a prospective monotherapy study. Epilepsia. 2008;49(3):438–445. doi:10.1111/j.1528-1167.2007.01429.x
   Web of Science ®Google Scholar
• Kodama Y, Koike Y, Kimoto H, et al. Binding parameters of valproic acid to serum protein in healthy adults at steady state. Ther Drug Monit. 1992;14(1):55–60. doi:10.1097/00007691-199202000-00009
   PubMed Web of Science ®Google Scholar
• Cramer JA, Mattson RH, Bennett DM, Swick CT. Variable free and total valproic acid concentrations in sole- and multi-drug therapy. Ther Drug Monit. 1986;8(4):411–415. doi:10.1097/00007691-198612000-00005
   Web of Science ®Google Scholar
• Bellver M, Sánchez M, Gonzalez A, Santos Buelga D, Domínguez-Gil A. Plasma protein binding kinetics of valproic acid over a broad dosage range: therapeutic implications. J Clin Pharm Ther. 1993;18(3):191–197. doi:10.1111/j.1365-2710.1993.tb00612.x
   Web of Science ®Google Scholar
• Patsalos PN, Zugman M, Lake C, James A, Ratnaraj N, Sander JW. Serum protein binding of 25 antiepileptic drugs in a routine clinical setting: a comparison of free non–protein-bound concentrations. Epilepsia. 2017;58(7):1234–1243. doi:10.1111/epi.13802
   PubMed Web of Science ®Google Scholar
• Ito M, Ikeda Y, Arnez JG, Finocchiaro G, Tanaka K. The enzymatic basis for the metabolism and inhibitory effects of valproic acid: dehydrogenation of valproyl-CoA by 2-methyl-branched-chain acyl-CoA dehydrogenase. BBA-Gen Subjects. 1990;1034(2):213–218. doi:10.1016/0304-4165(90)90079-C
   PubMed Web of Science ®Google Scholar
• Ghodke-Puranik Y, Thorn CF, Lamba JK, et al. Valproic acid pathway: pharmacokinetics and pharmacodynamics. Pharmacogenet Genom. 2013;23(4):236–241. doi:10.1097/FPC.0b013e32835ea0b2
   PubMed Web of Science ®Google Scholar
• Kiang TK, Ho PC, Anari MR, Tong V, Abbott FS, Chang TK. Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype. Toxicol Sci. 2006;2:261–271. doi:10.1093/toxsci/kfl096
   Web of Science ®Google Scholar
• Tan L, Yu JT, Sun YP, Ou JR, Song JH, Yu Y. The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients. Clin Neurol Neurosurg. 2010;112(4):320–323. doi:10.1016/j.clineuro.2010.01.002
   PubMed Web of Science ®Google Scholar
• Jiang D, Bai X, Zhang Q, et al. Effects of CYP2C19 and CYP2C9 genotypes on pharmacokinetic variability of valproic acid in Chinese epileptic patients: nonlinear mixed-effect modeling. Eur J Clin Pharmacol. 2009;65(12):1187–1193. doi:10.1007/s00228-009-0712-x
   PubMed Web of Science ®Google Scholar
• Budi T, Toth K, Nagy A, et al. Clinical significance of CYP2C9-status guided valproic acid therapy in children. Epilepsia. 2015;56(6):849–855. doi:10.1111/epi.13011
   PubMed Web of Science ®Google Scholar
• Wang C, Wang P, Yang LP, Pan J, Yang X, Ma HY. Association of cyp2c9, cyp2a6, acsm2a, and cpt1a gene polymorphisms with adverse effects of valproic acid in chinese patients with epilepsy. Epilepsy Res. 2017;132:64–69. doi:10.1016/j.eplepsyres.2017.02.015
   Web of Science ®Google Scholar
• Gielgens RC, Bok LA. Commentary on clinical significance of CYP2C9-status-guided valproic acid therapy in children. Epilepsia. 2016;57(8):1337·1342. doi:10.1111/epi.13452
   Web of Science ®Google Scholar
• Toth K, Budi T, Kiss A, et al. Phenoconversion of CYP2C9 in epilepsy limits the predictive value of CYP2C9 genotype in optimizing valproate therapy. Pers Mad. 2015;12:201–209.
   Web of Science ®Google Scholar
• Zhang JF, Zhang ZQ, Dong WC, Jiang Y. A new derivatization method to enhance sensitivity for the determination of low levels of valproic acid in human plasma. J Chromatogr Sci. 2014;52:1173–1180. doi:10.1093/chromsci/bmt167
   Web of Science ®Google Scholar
• Zhang ZQ, Dong WC, Yang XL, et al. The influence of plasma albumin concentration on the analysis methodology of free valproic acid by ultrafiltration and its application to therapeutic drug monitoring. Ther Drug Monit. 2015;37(6):776–782. doi:10.1097/FTD.0000000000000225
   Web of Science ®Google Scholar
• Depositario-Cabacar DF, Zelleke TG. Treatment of epilepsy in children with developmental disabilities. Dev Disabil Res Rev. 2010;16(3):239–247. doi:10.1002/ddrr.116
   Web of Science ®Google Scholar
• Singh BK, White-Scott S. Role of topiramate in adults with intractable epilepsy, mental retardation, and developmental disabilities. Seizure. 2002;11:47–50. doi:10.1053/seiz.2001.0571
   PubMed Web of Science ®Google Scholar
• Salpekar J. Neuropsychiatric effects of epilepsy in developmental disorders. Curr Opin Psychiatry. 2018;31(2):109–115. doi:10.1097/YCO.0000000000000392
   Web of Science ®Google Scholar
• Gao K, Zhang Y, Zhang L, et al. Large de novo microdeletion in epilepsy with intellectual and developmental disabilities, with a systems biology analysis. Adv Neurobiol. 2018;21:247–266.
   Google Scholar
• Lamm WW, Millichap JJ, Soares DC, et al. Novel de novo EEF1A2 missense mutations causing epilepsy and intellectual disability. Mol Genet Genomic Med. 2016;4(4):465–474. doi:10.1002/mgg3.219
   Web of Science ®Google Scholar
• Kong W, Zhang Y, Gao Y, et al. SCN8A mutations in Chinese children with early onset epilepsy and intellectual disability. Epilepsia. 2015;56(3):431–438. doi:10.1111/epi.12925
   Web of Science ®Google Scholar
• Zhang Y, Kong W, Gao Y, et al. Gene mutation analysis in 253 Chinese children with unexplained epilepsy and intellectual/developmental disabilities. PLoS One. 2015;10(11):e0141782. doi:10.1371/journal.pone.0141782
   PubMed Web of Science ®Google Scholar
• Ahlers FS, Benros ME, Dreier JW, Christensen J. Infections and risk of epilepsy in children and young adults: a nationwide study. Epilepsia. 2019;60(2):275–283. doi:10.1111/epi.14626
   Web of Science ®Google Scholar
• Lin CH, Lin WD, Chou IC, Lee IC, Hong SY. Epilepsy and neurodevelopmental outcomes in children with etiologically diagnosed central nervous system infections: a retrospective cohort study. Front Neurol. 2019;10:528. doi:10.3389/fneur.2019.00528
   Web of Science ®Google Scholar
• Lam SK, Lu WY, Weng WC, Fan PC, Lee WT. The short-term and long-term outcome of febrile infection-related epilepsy syndrome in children. Epilepsy Behav. 2019;95:117–123. doi:10.1016/j.yebeh.2019.02.033
   Web of Science ®Google Scholar
• Bartolini L, Theodore WH, Jacobson S, et al. Infection with HHV-6 and its role in epilepsy. Epilepsy Res. 2019;153:34–39. doi:10.1016/j.eplepsyres.2019.03.016
   PubMed Web of Science ®Google Scholar
• Bartolini L, Theodore WH, Jacobson S, Gaillard WD. Detection of HHV-6 and EBV and cytokine levels in saliva from children with seizures: results of a multi-center cross-sectional study. Front Neurol. 2018;9:834. doi:10.3389/fneur.2018.00834
   PubMed Web of Science ®Google Scholar
• Cha T, Choi YJ, Oh JW, et al. Respiratory syncytial virus-associated seizures in Korean children, 2011–2016. Korean J Pediatr. 2019;62(4):131–137. doi:10.3345/kjp.2018.07066
   PubMedGoogle Scholar
• Cruz-Cruz MDR, Gallardo-Elías J, Paredes-Solís S, Legorreta-Soberanis J, Flores-Moreno M, Andersson N. Factors associated with epilepsy in children in Mexico: a case-control study. Bol Med Hosp Infant Mex. 2017;74(5):334–340. doi:10.1016/j.bmhimx.2017.05.006
   Web of Science ®Google Scholar
• Nasreddine W, Dirani M, Atweh S, Makki A, Beydoun A. Determinants of free serum valproate concentration: a prospective study in patients on divalproex sodium monotherapy. Seizure. 2018;59:24–27. doi:10.1016/j.seizure.2018.04.012
   Web of Science ®Google Scholar
• Ho PC, Abbott FS, Zanger UM, Chang TK. Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes. Pharmacogenomics J. 2003;3:335–342. doi:10.1038/sj.tpj.6500210
   PubMed Web of Science ®Google Scholar
• Monostory K, Nagy A, Tóth K, et al. Relevance of CYP2C9 function in valproate therapy. Curr Neuropharmacol. 2019;17(1):99–106. doi:10.2174/1570159X15666171109143654
   PubMed Web of Science ®Google Scholar
• Goto S, Seo T, Murata T, et al. Population estimation of the effects of cytochrome P450 2C9 and 2C19 polymorphisms on phenobarbital clearance in Japanese. Ther Drug Monit. 2007;29(1):118–121. doi:10.1097/FTD.0b013e318030def0
   PubMed Web of Science ®Google Scholar
• Gunes A, Bilir E, Zengil H, et al. Inhibitory effect of valproic acid on cytochrome P450 2C9 activity in epilepsy patients. Basic Clin Pharmacol Toxicol. 2007;100(6):383–386. doi:10.1111/j.1742-7843.2007.00061.x
   PubMed Web of Science ®Google Scholar
• Smith RL, Haslemo T, Refsum H, Molden E. Impact of age, gender and CYP2C9/2C19 genotypes on dose-adjusted steady-state serum concentrations of valproic acid—a large-scale study based on naturalistic therapeutic drug monitoring data. Eur J Clin Pharmacol. 2016;72:1099–1104. doi:10.1007/s00228-016-2087-0
   PubMed Web of Science ®Google Scholar
• Gu XR, Yu SR, Peng QL, Ma M, Hu Y, Zhou B. Determination of unbound valproic acid in plasma using centrifugal ultrafiltration and gas chromatography: application in TDM. Anal Biochem. 2020;588:113475. doi:10.1016/j.ab.2019.113475
   Web of Science ®Google Scholar
• Itoh H, Suzuki Y, Fujisaki K, Sato Y, Takeyama M. Correlation between plasma ammonia level and serum trough concentration of free valproic acid in patients with epilepsy. Biol Pharm Bull. 2012;35(6):971–974. doi:10.1248/bpb.35.971
   Web of Science ®Google Scholar
• Drisaldi A, Weeda E, Meyens R, et al. Accuracy of valproic acid concentration correction based on serum albumin. Neurocrit Care. 2019;30(2):301–306. doi:10.1007/s12028-018-0627-4
   PubMed Web of Science ®Google Scholar
• Riker RR, Gagnon DJ, Hatton C, et al. Valproate protein binding is highly variable in ICU patients and not predicted by total serum concentrations: a case series and literature review. Pharmacotherapy. 2017;37(4):500–508. doi:10.1002/phar.1912
   Web of Science ®Google Scholar
• Schoemaker R, Wade JR, Stockis A. Brivaracetam population pharmacokinetics in children with epilepsy aged 1 month to 16 years. Eur J Clin Pharmacol. 2017;73(6):727–733. doi:10.1007/s00228-017-2230-6
   PubMed Web of Science ®Google Scholar
• Wu CC, Pai TY, Hsiao FY, Shen LJ, Wu FL. The effect of different carbapenem antibiotics (ertapenem, imipenem/cilastatin and meropenem) on serum valproic acid concentrations. Ther Drug Monit. 2016;38(5):587–592. doi:10.1097/FTD.0000000000000316
   Web of Science ®Google Scholar
• Šíma M, Hartinger J, Rulíšek J, Šachl R, Slanař O. Meropenem-induced valproic acid elimination: a case report of clinically relevant drug interaction. Prague Med Rep. 2017;118(2–3):105–109. doi:10.14712/23362936.2017.11
   Google Scholar